Salivary Gland Tumor Cell Biorepository

涎腺肿瘤是一种罕见的肿瘤，在美国每年约有3,300例新病例。虽然手术是这些肿瘤的主要治疗方式，但晚期不能切除的原发、复发和转移肿瘤通常是致命的。值得注意的是，涎腺恶性肿瘤的总体发病率与慢性粒细胞白血病(CML)相似，但联邦和私营研究企业对CML的研究远远超过唾液腺肿瘤。因此，在该领域工作的研究人员相对较少，而且还没有建立起供研究人员从事这类研究的临界数量的研究工具。 2006年10月，NCI和NIDCR召开了关于涎腺恶性肿瘤的生物学和治疗的第一次研讨会。得出的结论是，从基础生物学到治疗和患者管理，这一领域在各个方面都缺乏进展。更重要的是，研讨会揭示了组织标本、细胞系和动物模型等研究工具的匮乏，这些工具有助于促进该领域的基础研究和翻译研究。此外，还缺乏一个集中的努力来编目和收集这些可供校外社区使用的资源。 为了推动该领域的基础研究和转译研究，并最终改善公众健康，NIDCR牵头支持在一家在头颈部和唾液腺肿瘤生物学和病理学方面拥有已知专业知识的学术机构建立中央生物库。NIDCR指定MDACC的Adel El-Naggar博士领导中央生物库，他是国内和国际公认的唾液腺肿瘤生物学和病理学专家。El-Naggar博士通过一个卫星中心联盟协调努力，在MDACC建立一个集中的生物储存库，这些中心同意向该生物储存库捐赠生物标本。他确定了一批唾液腺病理学和生物学的核心专家，他们可以帮助识别和分类与诊断、病理、治疗和结果数据有关的生物标本。通过这个联合体，生物信息库存储和编目新鲜的冷冻唾液腺肿瘤组织和石蜡块(如果适用，还包括匹配的血清、唾液、淋巴细胞)以及相关的临床数据。预计将通过一个可在线搜索的基于网络的电子界面，为获取有关生物检疫的信息和相关临床数据提供便利。

Salivary gland tumors are rare neoplasms with approximately 3,300 new cases per year in the US. While surgery is the main modality of treatment for these tumors, advanced unresectable primary, recurrent and metastatic tumors are generally fatal. It is important to note that the overall incidence for salivary gland malignancies mimics those of chronic myelocytic leukemias (CML), yet federal and private research enterprises for CML far exceed those for the salivary gland tumors. As a result, there have been relatively few investigators working in the field and a critical mass of research tools for investigators to engage in this type of research has not been established. In October 2006, NCI and NIDCR convened the first workshop on the ¿Biology and Treatment of Malignant Salivary Gland Tumors.¿ It was concluded that this field is suffering from lack of progress in all aspects, from basic biology to therapy and patient management. More importantly, the workshop revealed that there is a paucity of research tools such as tissue specimens, cell lines, and animal models that are instrumental in promoting the basic and translational research in the field. Furthermore, a centralized effort to catalogue and collect these resources that can be made available to the extramural community is lacking. In an effort to advance basic and translational research in this field and ultimately improve public health, NIDCR led the effort to support the establishment of a centralized biorepository at an academic institution with known expertise in head and neck and salivary gland tumor biology and pathology NIDCR identified Dr. Adel El-Naggar at MDACC, a nationally and internationally recognized expert in salivary gland tumor biology and pathology, to lead the centralized biorepository. Dr. El-Naggar coordinated the effort to establish a centralized biorepository at MDACC through a consortium of satellite centers that agreed to contribute biospecimens to the biorepository. He identified a core number of experts in salivary gland pathology and biology who could help identify and catalogue biospecimens linked to diagnostic, pathologic, treatment, and outcome data. Through this consortium, the biorepository stores and catalogues fresh frozen salivary gland tumor tissues and paraffin blocks (with matched serum, saliva, lymphocytes, if applicable), as well as associated clinical data. It is anticipated that access to information on biospecimens and associated clinical data will be facilitated through a web-based electronic interface that is searchable online.